

Lal et al., 09/002,485, filed December 31, 1997  
(PF-0459)

Exhibit "I" attached to Declaration of John C.  
Rockett, Ph.D.



**Agilent Technologies**

[About Agilent](#) | [Products & Services](#) | [Industries](#) | [International](#) | [Online Stores](#)

[Worldwide Home](#) > [About Agilent](#) > [News@Agilent](#) > [Press Releases](#)

**News@Agilent**

## **Agilent Technologies ships whole human genome on single microarray to gene expression customers for evaluation**

**Company to introduce first commercial whole human microarray by end of year**

*PALO ALTO, Calif., Oct. 2, 2003*

**Press Releases**

- ▶ [Communi](#)
- ▶ [Corporate](#)
- ▶ [Electronic](#)
- ▶ [Life Scien](#)  
[Chemical](#)

▶ [Archives](#)

**Search Agile**

**Quick Links**

[Jump to pa](#)

Agilent Technologies Inc. (NYSE: A) today announced it has shipped whole human-genome microarrays to customers for testing and evaluation. The whole genome microarray is based on Agilent's new double-density format, which can accommodate 44,000 features on a single 1" x 3" glass-slide microarray. The new platform enables drug-discovery and disease researchers to perform whole-genome screening at a lower cost and with higher reproducibility.

"This is an important step toward our release of the first whole human-genome microarray product, which is expected to be available for order before the end of the year," said Barney Saunders, vice president and general manager of Agilent's BioResearch Solutions Unit. "Customers have long wanted a one-sample, one-chip format with the increased sensitivity associated with 60-mer probes. The cost savings and high-quality performance make this product a compelling alternative for scientists who make their own microarrays."

Agilent's microarrays are based on the industry-standard 1" x 3" (25mm x 75mm) format, which is compatible with most commercial microarray scanners. All Agilent commercial microarrays are developed using content from public databases and proprietary sources, with full sequence and annotation information made available to customers. Gene sequences for probes are developed using algorithms and then validated empirically through iterative wet-lab testing procedures. The result is a microarray comprised of functionally validated probes, with the most up-to-date and comprehensive genome information commercially available.

Advantages of the double-density format include:

- Lower cost. Not only is one microarray less expensive than two, it requires fewer reagents and reduces instrumentation demands.
- Streamlined workflow. Researchers need prepare and process only one microarray instead of two. This also results in fewer steps in the subsequent data analysis.
- Greater reproducibility. Use of a single microarray further reduces unnecessary variability in experimental conditions.
- Smaller sample use. A smaller quantity of sample material is required to perform an experiment.

### **Availability**

Agilent's Whole Human Genome Microarray is expected to be available for order by the end of the year.

### **About Agilent Technologies**

Agilent Technologies Inc. (NYSE: A) is a global technology leader in communications, electronics, life sciences and chemical analysis. The company's 30,000 employees serve customers in more than 110 countries. Agilent had net revenue of \$6 billion in fiscal year 2002. Information about Agilent is available

on the Web at [www.agilent.com](http://www.agilent.com).

#### **Forward-Looking Statements**

This news release contains forward-looking statements (including, without limitation, statements relating to Agilent's expectation that its whole-genome microarray platform will be available for order before the end of 2003) that involve risks and uncertainties that could cause results to differ materially from management's current expectations. These and other risks are detailed in the company's filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the year ended Oct. 31, 2002, its Quarterly Report on Form 10-Q for the quarter ended July 31, 2003 and its Current Report on Form 8-K filed Aug. 18, 2003. The company assumes no obligation to update the information in this press release.

###

#### **Contact:**

Christina Maehr  
+1 408 553 7205  
[christina\\_maehr@agilent.com](mailto:christina_maehr@agilent.com)

To send feedback about this site: [Contact Webmaster](#)



© Agilent 2000-2003

[Terms of Use](#)

[Privacy](#)